Видео ютуба по тегу Nectin-4

NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
LY4101174, a novel nectin-4-targeting ADC in solid tumors
LY4101174, a novel nectin-4-targeting ADC in solid tumors
Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
Nectin-4 is Widely Expressed in Head and Neck Squamous Cell Carcinoma | Oncotarget
Nectin-4 is Widely Expressed in Head and Neck Squamous Cell Carcinoma | Oncotarget
Phase II EPIC trial: enfortumab vedotin in advanced pancreatic adenocarcinoma
Phase II EPIC trial: enfortumab vedotin in advanced pancreatic adenocarcinoma
Уротелиальный рак мочевого пузыря на 4-м ежегодном национальном саммите по ГМО
Уротелиальный рак мочевого пузыря на 4-м ежегодном национальном саммите по ГМО
NEXUS-01: LY4052031, a nectin-4 ADC, in urothelial carcinoma and other tumors
NEXUS-01: LY4052031, a nectin-4 ADC, in urothelial carcinoma and other tumors
The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B & More
The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B & More
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothel...
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothel...
Resistance mechanisms associated with the use of ADCs in UC
Resistance mechanisms associated with the use of ADCs in UC
Энфортумаб Ведотин-Пембролизумаб при распространенном уротелиальном раке | НЭМ
Энфортумаб Ведотин-Пембролизумаб при распространенном уротелиальном раке | НЭМ
Oncology 1
Oncology 1
Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma
Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma
RLTs in Bladder Cancer: Nectin-4 Targeting
RLTs in Bladder Cancer: Nectin-4 Targeting
Nectin
Nectin
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Bladder TCC: ASCO 2018 Highlights (BMIC-049)
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Bladder TCC: ASCO 2018 Highlights (BMIC-049)
Nectin-4 and Platinum Chemotherapy in mUC #oncology #pencis #researchers #Chemotherapy #youtubeshort
Nectin-4 and Platinum Chemotherapy in mUC #oncology #pencis #researchers #Chemotherapy #youtubeshort
Enfortumab mode of action
Enfortumab mode of action
Enfortumab vedotin: targeting bladder cancer
Enfortumab vedotin: targeting bladder cancer
Enfortumab vedotin for the treatment of advanced urothelial cancer
Enfortumab vedotin for the treatment of advanced urothelial cancer